PL3651749T3 - Sposób leczenia urazowego uszkodzenia mózgu - Google Patents

Sposób leczenia urazowego uszkodzenia mózgu

Info

Publication number
PL3651749T3
PL3651749T3 PL17743406.5T PL17743406T PL3651749T3 PL 3651749 T3 PL3651749 T3 PL 3651749T3 PL 17743406 T PL17743406 T PL 17743406T PL 3651749 T3 PL3651749 T3 PL 3651749T3
Authority
PL
Poland
Prior art keywords
brain injury
traumatic brain
treating traumatic
treating
injury
Prior art date
Application number
PL17743406.5T
Other languages
English (en)
Inventor
Mattheus Cornelis De Wilde
Robert Johan Joseph Hageman
Original Assignee
N.V. Nutricia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N.V. Nutricia filed Critical N.V. Nutricia
Publication of PL3651749T3 publication Critical patent/PL3651749T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17743406.5T 2017-07-12 2017-07-12 Sposób leczenia urazowego uszkodzenia mózgu PL3651749T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2017/050467 WO2019013615A1 (en) 2017-07-12 2017-07-12 METHOD OF TREATING TRAUMATIC BRAIN INJURY

Publications (1)

Publication Number Publication Date
PL3651749T3 true PL3651749T3 (pl) 2025-01-27

Family

ID=59399463

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17743406.5T PL3651749T3 (pl) 2017-07-12 2017-07-12 Sposób leczenia urazowego uszkodzenia mózgu

Country Status (8)

Country Link
US (1) US20200261488A1 (pl)
EP (1) EP3651749B1 (pl)
CN (1) CN110869010A (pl)
AU (1) AU2017423466B2 (pl)
BR (1) BR112020000602A2 (pl)
ES (1) ES2995536T3 (pl)
PL (1) PL3651749T3 (pl)
WO (1) WO2019013615A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019013616A1 (en) 2017-07-12 2019-01-17 N.V. Nutricia TREATMENT OF TRAUMATIC BRAIN INJURY
US20230398088A1 (en) * 2020-10-30 2023-12-14 The Trustees Of The University Of Pennsylvania Lipid Prophylactic Brain Injury Treatment
AU2022249084A1 (en) * 2021-04-01 2023-11-09 R.P. Scherer Technologies, Llc Phospholipids as anion chelating agents in pharmaceutical formulations
CN113679835A (zh) * 2021-09-16 2021-11-23 四川力量科技有限公司 一种脑卒中后遗症康复用产品及其制备方法
WO2023041776A1 (en) 2021-09-17 2023-03-23 N.V. Nutricia Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases
AU2023300565A1 (en) 2022-07-01 2024-12-12 N.V. Nutricia Nutritional composition for neurodegeneration and neurotrauma
WO2025003349A1 (en) 2023-06-30 2025-01-02 N.V. Nutricia Nutritional composition for neurodegeneration and neurotrauma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
CN103371993A (zh) 2012-04-27 2013-10-30 复旦大学 n-3不饱和脂肪酸在制备防治创伤性脑损伤药物中的用途
US20140256813A1 (en) * 2013-03-08 2014-09-11 Nordic Naturals, Inc. Methods for the treatment of brain injury using omega-3 fatty acids
WO2015115885A1 (en) * 2014-01-31 2015-08-06 N.V. Nutricia Method for reducing white matter lesions, white matter hyperintensities (wmh), leukoaraiosis or periventricular white matter disease in elderly

Also Published As

Publication number Publication date
EP3651749C0 (en) 2024-09-04
AU2017423466A1 (en) 2019-01-17
EP3651749B1 (en) 2024-09-04
ES2995536T3 (en) 2025-02-10
CN110869010A (zh) 2020-03-06
WO2019013615A1 (en) 2019-01-17
US20200261488A1 (en) 2020-08-20
EP3651749A1 (en) 2020-05-20
AU2017423466B2 (en) 2024-02-22
BR112020000602A2 (pt) 2020-07-14
AU2017423466A2 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
IL267934A (en) Glyceryl 3-hydroxybururates Traumatic brain injury
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
ZA201705673B (en) Methods for treating skin
ZA201706616B (en) Method for treating cancer
HUE064310T2 (hu) Kezelõberendezés és eljárás munkadarabok kezelésére
IL257691A (en) A method for treating cancer
IL293712A (en) Methods for treating mild brain injury
ZA201706035B (en) Method of treating a brain tumor
SG11202100682YA (en) Method for treating epilepsy
ZA202001141B (en) Zeolite after treatment method
GB2567616B (en) Treatment method
IL251262A0 (en) Methods for treating traumatic brain injury
ZA202001880B (en) Compositions and methods for treating brain injury
IL258988A (en) Methods for treating epilepsy
IL267199A (en) A method for treating epilepsy
IL255506A (en) A method for treating a neurological disease
GB2571601B (en) Treatment method
SG11202001806TA (en) Treatment method
IL276577A (en) Methods for treating cardiac injury
EP3615013C0 (en) THIOL COMPOUNDS FOR TREATING ACUTE TRAUMATIC BRAIN INJURY
PT3172977T (pt) Método para a produção de peças de vestuário ou ligaduras
IL250658A0 (en) Methods for treating mild brain injury
SG10201508795XA (en) Method for treating cancer
SI3426237T1 (sl) Postopek za zdravljenje možganske atrofije
HUE068710T2 (hu) NK1-antagonista kombináció és eljárás szinukleinopátia kezelésére